
Novo Nordisk's novel weight loss drug Wegovy has the potential to at least double or triple the market, writes investment banking company Jefferies in a report.
The bank has recently hosted a teleconference involving an expert in obesity and diabetes treatment, and the financial analyst bases its estimate on the input from the participating expert.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app